Polyrizon News and Resources

Polyrizon, a biotech company focused on innovative intranasal hydrogels, has announced the commencement of Good Manufacturing Practice (GMP) manufacturing preparations for its PL-14 allergy blocker. This milestone is a critical step in readiness for the company’s planned 2025 clinical trial.